doi:10.1038/nature14292

SUPPLEMENTARY METHODS

Antibodies for flow cytometry. Antibodies for flow cytometery used in the mouse and human experiments are provided in the tables below.

MOUSE EXPERIMENTS			
Antibody	**Clone**	**Fluorphore**	**Company**
Rat IgG_{2a}	B39-4	PE	BD Biosciences
CD274	MIH5	PE	BD Biosciences
CD45.2	104	BV570 and AF700	Biolegend
CD3	17A2	BV650	Biolegend
CD3	145-2C11	PE/Cy5	Biolegend
CD4	RM4-5	V450	BD Biosciences
CD4	RM4-5	PerCP-Cy5.5	eBioscience
CD8a	53-6.7	PE-CF594	BD Biosciences
CD8a	53-6.7	eFluor 450	eBioscience
B220	RA3-6B2	APC eFluor 780	eBioscience
NK1.1	PK136	APC eFluor 780	eBioscience
CD279	RMPI-30	PE/Cy7	Biolegend
CD44	IM7	BV785 and AF700	Biolegend
F4/80	BM8	PE/Cy7	Biolegend
CD11c	HL3	V450	BD Biosciences
CD11c	N418	BV605	Biolegend
CD11b	M1/70	PerCP-Cy5.5 and PE	BD Biosciences
Ly-6G/Ly-6C	RB6-8C5	APC/Cy7	BD Biosciences
CD49b	DX5	APC/Cy7	Biolegend
CD49b	DX5	FITC	BD Biosciences
FOXP3	FJK-16s	PE and APC	eBioscience
Eomes	Dan11Mag	eFluor 660	eBioscience
Ki67	B56	FITC	BD Biosciences
Granzyme B	GB11	PE Texas Red	Life Technologies

HUMAN EXPERIMENTS			
Antibody	**Clone**	**Fluorphore**	**Company**
CD14	M5E2	BD Horizon V500	BD Biosciences
CD16	3G8	BD Horizon V500	BD Biosciences
CD19	HIB19	BD Horizon V500	BD Biosciences
CD3	OKT-3	Qdot 585	NA
CD45RA	MEM-56	Qdot 605	Invitrogen
CD4	RPA-T4	eFluor 650 NC	eBioscience
PD1	EH12.2H7	Brilliant Violet 711	BioLegend
CD27	O323	Brilliant Violet 785	Biolegend
Granzyme B	GB11	PE-Texas Red	Invitrogen
Ki67	B56	Alexa Fluor 700	BD Biosciences
CD8	RPA-T8	APC-eFluor 780	eBioscience

Guide RNA sequences. Gene block contains 20 bp target size (N), U6 promoter, gRNA scaffold, and termination signal. The sequence and sequences for each guide used are as follows.

TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCGGTACCAAGGTCG
GGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGT
TAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGAC
GTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATC
ATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGAC
GAAACACCG**NNNNNNNNNNNNNNNNNNN**GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG
GCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTCTAGACCCAGC
TTTCTTGTACAAAGTTGGCATTA

G1: GGCTCCAAAGGACTTGTACG
G2: GACTTGTACGTGGTGGAGTA
G3: GTATGGCAGCAACGTCACGA